Leeward Financial Partners LLC Acquires 16,113 Shares of Illumina, Inc. $ILMN

Leeward Financial Partners LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 16,113 shares of the life sciences company’s stock, valued at approximately $4,410,000. Illumina makes up approximately 1.2% of Leeward Financial Partners LLC’s holdings, making the stock its 29th largest position.

A number of other hedge funds also recently made changes to their positions in the stock. Sigma Planning Corp increased its stake in Illumina by 91.1% in the third quarter. Sigma Planning Corp now owns 6,980 shares of the life sciences company’s stock valued at $1,910,000 after acquiring an additional 3,327 shares during the last quarter. Signaturefd LLC lifted its stake in Illumina by 8.4% during the third quarter. Signaturefd LLC now owns 5,897 shares of the life sciences company’s stock worth $1,614,000 after purchasing an additional 457 shares during the last quarter. Evergreen Capital Management LLC lifted its stake in Illumina by 0.5% during the third quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after purchasing an additional 50 shares during the last quarter. Gibbs Wealth Management lifted its stake in Illumina by 11.2% during the third quarter. Gibbs Wealth Management now owns 2,432 shares of the life sciences company’s stock worth $666,000 after purchasing an additional 245 shares during the last quarter. Finally, Wedbush Securities Inc. boosted its holdings in shares of Illumina by 4.9% in the 3rd quarter. Wedbush Securities Inc. now owns 1,714 shares of the life sciences company’s stock worth $469,000 after purchasing an additional 80 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s upcoming quarterly report could benefit from strong clinical demand, NovaSeq X adoption, new instrument placements, and consumables growth. Analysts also expect year-over-year earnings growth and see potential for an earnings beat, although research-market weakness remains a concern. ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
• Positive Sentiment: The company launched three early-access capabilities for its BioInsight Platform—Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts. The tools expand Illumina’s AI-driven variant prioritization, sequencing analysis, and genomic-data workflow offerings, potentially increasing the strategic importance of software and data services. How Investors May Respond To Illumina BioInsight AI Rollout
• Neutral Sentiment: Illumina is expected to report quarterly results next week. The event is a major near-term catalyst, with investor attention likely centered on clinical demand, NovaSeq X placements, consumables revenue, and management’s outlook. Illumina Expected to Release Quarterly Earnings on Thursday
• Neutral Sentiment: The consensus price target was raised 19.65% to $250.77, signaling improved analyst expectations, but that target remains below Illumina’s recent trading level and may limit upside if not revised further. Illumina Consensus Price Target Increased
• Negative Sentiment: Stephens downgraded Illumina to Equal Weight, reducing a potential source of buying pressure and reflecting a more cautious view of the stock’s risk-reward profile. Stephens Downgrades Illumina to Equal Weight
• Negative Sentiment: Illumina recently fell alongside Twist Bioscience and other AI- and genomics-related stocks in a broad technology selloff, indicating that sector sentiment—not company-specific news—has also been driving volatility. Twist Bioscience and Illumina Slide as AI and Genomics Stocks Sell Off

Illumina Price Performance

ILMN stock opened at $269.42 on Monday. The firm has a market cap of $40.68 billion, a P/E ratio of 50.26, a P/E/G ratio of 3.82 and a beta of 1.41. The firm’s fifty day moving average is $242.35 and its 200 day moving average is $191.54. Illumina, Inc. has a 52 week low of $94.00 and a 52 week high of $309.35. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm posted $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Activity at Illumina

In other news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 2,061,850 shares of company stock valued at $436,479,102 in the last quarter. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ILMN. Stifel Nicolaus increased their price objective on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Sanford C. Bernstein reissued a “market perform” rating and set a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Royal Bank Of Canada boosted their target price on Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Citigroup upped their target price on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Finally, Guggenheim upped their target price on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $234.41.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.